Inclusion Criteria:

1. Patients with histologic confirmation of invasive HER2/neu-negative breast cancer
(IHC 0-1+ or FISH-negative) that have received complete anthracycline and taxane
neoadjuvant systemic therapy and that at the time of surgery are expected to have
significant residual disease. Therapy should include at least 4 cycles of an
anthracycline-based regimen (AC, FAC, FEC) and 12 weeks of a taxane-based regimen
(weekly paclitaxel, every 3-week docetaxel).

2. Patients who did not complete therapy due to disease progression are eligible.

3. Age >/= 18 years

4. Patients with bilateral breast cancers are eligible.

5. Patients should have a Karnofsky performance scale of =/> 70%.

6. Patient should have adequate bone marrow function, as defined by peripheral
granulocyte count of >/= 1500/mm^3, and platelet count >/= 100000 mm^3.

7. Patients must have adequate liver function with a bilirubin within normal laboratory
values. Alkaline phosphatase and transaminases (ALT and AST) may be up to 1.5 x upper
limit of normal (ULN) of the institution.

8. Patients should have adequate renal function with creatinine levels within normal
range.

9. Negative serum pregnancy test for a woman of childbearing potential.

10. Women of childbearing potential (WOCP) must use a reliable and appropriate
contraceptive method during the study and 6 months after chemotherapy is completed.
WOCBP are women who are not menopausal for 12 months or had no previous surgical
sterilization.

11. Patients must agree to have study tissue collections and blood sample collections.

12. Patients must sign an informed consent indicating that they are aware of the
investigational nature of the study, in keeping with institutional policy.

13. Patients should have their surgical tissues evaluated for RCB and be used for
correlative studies.

14. Sexually active women of childbearing potential must use an effective method of birth
control during the course fo the study, in a manner such that risk of failure is
minimized. Prior to study enrollment, women of childbearing potential (WOCBP) must be
advised of the importance of avoiding pregnancy during trial participation and the
potential risk factors for an unintentional pregnancy. In addition, men enrolled on
this study should understand the risks to any sexual partner of childbearing
potential and should practice an effective method of birth control.

15. All WOCBP MUST have a negative pregnancy test within 7 days prior to first receiving
investigational product. If the pregnancy test is positive, the patient must not
receive investigational product and must not be enrolled in the study. In addition,
all WOCBP will be instructed to contact the Investigator immediately if they suspect
they might be pregnant (e.g., missed or late menstrual period) at any time during
study participation. The PI will immediately notify BMS in the event of a confirmed
pregnancy in a patient participating in the study.

Exclusion Criteria:

1. Patients whose tumors express HER2 protein or have HER2/neu gene amplification.

2. Patients with a history of other invasive malignancies diagnosed and treated within
the previous 5 years, except non-melanoma skin cancer and non-invasive cervical
cancer

3. Other concurrent severe and/or uncontrolled medical disease which could compromise
participation in the study (i.e., uncontrolled diabetes, uncontrolled hypertension,
severe infection, severe malnutrition, unstable angina, or congestive heart failure -
New York Heart Association Class III or IV, ventricular arrhythmias, active ischemic
heart disease, myocardial infarction within six months, chronic liver or renal
disease, active upper GI tract ulceration)

4. Patients with a pre-existing peripheral neuropathy > grade 1.

5. Evidence of distant metastases.